<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification of diabetes mellitus and genetic diabetic syndromes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification of diabetes mellitus and genetic diabetic syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Classification of diabetes mellitus and genetic diabetic syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ashok Balasubramanyam, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Traditionally, diabetes has been classified into type 2 diabetes (which accounts for approximately 90 percent of cases of diabetes in the United States, Canada, and Europe) and type 1 diabetes (which accounts for another 5 to 10 percent of cases). The remainder are due to specific etiologic or pathophysiologic factors  (<a class="graphic graphic_table graphicRef59403" href="/z/d/graphic/59403.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Other forms of diabetes with variable pathophysiology are emerging that do not fit the typical phenotypes of type 1 or type 2 diabetes and are collectively termed "atypical diabetes." Known monogenic causes of diabetes (eg, those causing maturity onset diabetes of the young or neonatal diabetes) represent a fraction of these cases of atypical diabetes. </p><p>The genetic bases of common forms of type 1 and type 2 diabetes remain complex, with common gene variants individually contributing only small degrees of risk or protection. Furthermore, the worldwide epidemic of overweight and obesity has superimposed some aspects of the pathophysiology of type 2 diabetes (eg, those associated with increased adiposity) across all other types.</p><p>The current classification of diabetes mellitus will be reviewed here, together with brief descriptions of some emerging forms of atypical diabetes. The definition and diagnostic criteria for diabetes mellitus are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TYPE 1 DIABETES</span></p><p class="headingAnchor" id="H403506088"><span class="h2">Classic phenotype</span><span class="headingEndMark"> — </span>Type 1 diabetes is characterized by destruction of the pancreatic beta cells, leading to absolute insulin deficiency. This is usually due to autoimmune destruction of the beta cells. Testing for islet cell antibodies (ICA) or other islet autoantibodies (antibodies to glutamic acid decarboxylase 65 [GAD65]; insulin; the tyrosine phosphatases, insulinoma-associated protein 2 [IA-2] and IA-2 beta; and zinc transporter 8 [ZnT8]) in serum is important; positive autoantibody titers (particularly if two or more autoantibodies are positive) indicate autoimmune or "type 1A" diabetes [<a href="#rid2">2</a>]. However, some patients with absolute insulin deficiency have no evidence of autoimmunity and have no other known cause for beta cell destruction. The classification system of the American Diabetes Association (ADA) applies the term "idiopathic" or "type 1B" diabetes to refer to these patients; these terms could encompass patients who may have islet autoimmunity that is not detected by the currently measured autoantibodies, as well as an array of nonautoimmune pathophysiologic processes leading to near-complete loss of beta cell function. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p>The ADA classification of diabetes mellitus does not fully capture the recognized clinical heterogeneity of patients with diabetes. Other classification schemes have been proposed, accounting for beta cell autoimmunity, beta cell function, clinical features, and body weight. The high prevalence of overweight/obesity in the population has further complicated classification systems with an added element of insulin resistance even in type 1 diabetes. (See  <a class="medical medical_review" href="/z/d/html/1775.html" rel="external">"Syndromes of ketosis-prone diabetes mellitus", section on 'Classification of KPD'</a>.)</p><p>The emergence of atypical phenotypes of both type 1 and type 2 diabetes emphasizes the need for a better classification of diabetes, ideally on an etiologic basis.</p><p class="headingAnchor" id="H247196672"><span class="h2">Latent autoimmune diabetes in adults (LADA)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of LADA may be made in individuals with adult-onset diabetes who are positive for at least one diabetes autoantibody but exhibit prolonged preservation of insulin secretion and a more gradual onset of clinical diabetes than typical type 1 diabetes in children and adolescents. LADA may be considered a slowly progressive variant of type 1 diabetes. Patients with LADA are a heterogeneous group with variable titers of antibodies, body mass index (BMI), and rates of progression to insulin dependence [<a href="#rid3">3</a>]. Adults with LADA may not require insulin treatment at diagnosis but typically progress to insulin dependence after several months to years [<a href="#rid4">4-6</a>]. </p><p></p><p class="bulletIndent1">The clinical utility of the diagnosis lies in the identification of patients with a clinical course that will differ from the usual course of patients with type 2 diabetes [<a href="#rid1">1,7</a>]. Patients with LADA may differ from patients with classic type 2 diabetes and often present with a lower BMI, an earlier age of diabetes onset, and a personal or family history of autoimmune disease. A screening tool utilizing these clinical features has been developed to prompt islet autoantibody testing in adults with newly diagnosed type 2 diabetes in whom LADA should be suspected [<a href="#rid8">8</a>]. The presence and degree of elevation of anti-GAD or anti-ICA antibodies can help predict accelerated disease progression, an earlier requirement for insulin therapy, subtherapeutic responses to oral hypoglycemic medications, and greater risk of ketoacidosis [<a href="#rid3">3,4,9-12</a>]. A diagnosis of LADA therefore helps establish expectations for the disease course and informs monitoring and management strategies. (See <a class="local">'Distinguishing type 1 from type 2 diabetes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Older studies in predominantly Scandinavian populations that have a relatively high prevalence of type 1 diabetes have suggested that as many as 7.5 to 10 percent of adults with apparent type 2 diabetes, based on older age of onset, may have circulating autoantibodies directed against pancreatic beta cell antigens (ICA or GAD65) [<a href="#rid9">9,13,14</a>]. The prevalence of LADA is lower among patients diagnosed with type 2 diabetes in the more diverse United States population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – In genotyping analyses, LADA shares genetic features of both type 1 and type 2 diabetes [<a href="#rid15">15-17</a>]. As an example, one analysis showed that relative to healthy individuals, patients with LADA shared an increased frequency of an <em>HLA-DQB1</em> genotype with patients with type 1 diabetes and of a variant in the transcription factor 7-like 2 (<em>TCF7L2</em>) gene with patients with type 2 diabetes [<a href="#rid15">15</a>]. The variant in <em>TCF7L2</em> has been shown to increase the risk for type 2 diabetes in several populations, and the effect size was similar for LADA and type 2 diabetes [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Genetic susceptibility'</a> and  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2899082431"><span class="h2">Currently unclassified forms of autoimmune diabetes in adults</span><span class="headingEndMark"> — </span>The definition of LADA (see <a class="local">'Latent autoimmune diabetes in adults (LADA)'</a> above) is based on the presence of circulating type 1 diabetes-associated islet autoantibodies in adults. This definition does not include adult patients diagnosed with type 2 diabetes who have islet autoimmunity marked either by novel, non-type 1 diabetes-associated islet autoantibodies [<a href="#rid18">18</a>] or by cellular (eg, T cell) autoimmune biomarkers rather than humoral (autoantibody) biomarkers. Increasing evidence suggests that a substantial proportion of patients with an apparent phenotype of type 2 diabetes have T cell-mediated islet autoimmunity that contributes to progressive beta cell dysfunction and defective insulin secretion [<a href="#rid19">19</a>]. This form of autoimmune diabetes currently remains unclassified, in part because standardized clinical tests for T cell-mediated islet autoimmunity are not widely available.</p><p class="headingAnchor" id="H4"><span class="h1">TYPE 2 DIABETES</span></p><p class="headingAnchor" id="H287553060"><span class="h2">Classic phenotype</span><span class="headingEndMark"> — </span>Type 2 diabetes is the most common phenotypic form of diabetes in adults and is characterized by hyperglycemia and variable degrees of insulin resistance and deficiency. Its prevalence rises markedly with increasing degrees of obesity. Insulin resistance and insulin deficiency can arise through genetic or environmental influences, making it difficult to determine the exact cause in an individual patient. In addition, hyperglycemia itself can impair pancreatic beta cell function and exacerbate insulin resistance, through a mechanism termed "glucotoxicity." (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H270106199"><span class="h2">DKA in type 2 diabetes</span><span class="headingEndMark"> — </span>Diabetic ketoacidosis (DKA) was thought to be rare in patients with an apparent phenotype of type 2 diabetes, but it can occur in specific situations:</p><p class="bulletIndent1"><span class="glyph">●</span>DKA may occur due to severe stresses such as acute myocardial infarction, major trauma, or sepsis that provoke secretion of counterregulatory hormones that worsen insulin resistance in the face of markedly impaired insulin secretion; these patients are unable to respond to the increased insulin demand, potentially leading to DKA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DKA in the absence of a clinically apparent stressor may be the initial presentation of diabetes in patients with an apparent phenotype of type 2 diabetes who have a subtype of ketosis-prone diabetes. (See  <a class="medical medical_review" href="/z/d/html/1775.html" rel="external">"Syndromes of ketosis-prone diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2877261059"><span class="h2">Heterogeneity of type 2 diabetes</span><span class="headingEndMark"> — </span>Machine-learning approaches such as cluster analysis of large, comprehensive datasets of patients with type 2 diabetes have revealed clinically relevant subtypes of type 2 diabetes. Based on clinical parameters, five subtypes were defined: severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD) [<a href="#rid20">20</a>]. Originally derived from data in a Scandinavian cohort, these phenotypic subtypes have been described in other populations using similar clustering methods. Genomic sequence data from cohorts of patients with type 2 diabetes have yielded a range of genetic subtypes as well, each with associated genetic loci [<a href="#rid21">21</a>]. Subtypes derived from these analyses include those with decreased pancreatic beta cell function (with either increased or decreased proinsulin levels) and those with increased insulin resistance (associated with features of obesity, lipodystrophy, or abnormal hepatic lipid metabolism). (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Subtypes of diabetes based on pathogenesis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">DISTINGUISHING TYPE 1 FROM TYPE 2 DIABETES</span><span class="headingEndMark"> — </span>With the explosion of diabetes worldwide and the emergence of variant phenotypes, it has become increasingly difficult to distinguish type 1 from atypical presentations of type 2 diabetes  (<a class="graphic graphic_table graphicRef83072" data-inline-graphics="83072" href="/z/d/graphic/83072.html" rel="external">table 2</a>). Patients with type 1 diabetes may have at presentation or rapidly develop an absolute requirement for insulin therapy. However, many patients with type 2 diabetes lose beta cell function over time and require insulin for glucose management. Thus, need for insulin therapy per se does not distinguish type 1 from type 2 diabetes. As noted above, diabetic ketoacidosis (DKA) cannot be relied upon as an absolute indicator that the patient has type 1 diabetes or that long-term insulin therapy will be required. (See  <a class="medical medical_review" href="/z/d/html/1775.html" rel="external">"Syndromes of ketosis-prone diabetes mellitus"</a>.)</p><p>Patients with type 1 diabetes may coincidentally have pathophysiologic elements of type 2 diabetes. In the past, poor glycemic management prevented most individuals with type 1 diabetes from gaining weight. Intensive therapy now commonly used to manage type 1 diabetes has contributed to a prevalence of overweight and obesity in the type 1 diabetes population that is similar to the prevalence in the general population. Insulin resistance and other features of type 2 diabetes may be evident in such patients with type 1 diabetes, especially those who also have a family history of type 2 diabetes [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to perform islet autoantibody testing</strong> – Given the overlap between type 1 and type 2 diabetes, the practical utility of identifying any underlying islet autoimmune process, and the emergence of many atypical forms of diabetes, clinicians should consider islet autoantibody testing in all patients who lack a classic phenotype of overweight-associated type 2 diabetes.</p><p></p><p class="bulletIndent1">We measure islet autoantibodies in patients with any clinical characteristics or presentations that are atypical for type 2 diabetes, including the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have a subtherapeutic response to initial therapy with sulfonylureas or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adults without overweight or obesity (body mass index [BMI] &lt;25 kg/m<sup>2</sup> or &lt;23 kg/m<sup>2</sup> for persons of Asian descent)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with a personal or family history of autoimmune disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children and young adults (age &lt;30 years)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adults who present with unintentional weight loss or ketoacidosis at the time of diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Which islet autoantibodies should be measured?</strong> – At least two autoantibodies (ie, islet cell antibodies [ICA] and GAD65) or an autoantibody panel (insulin-associated antibodies [IAA], GAD65, insulinoma-associated protein 2 [IA-2], and zinc transporter 8 [ZnT8]) can be measured. Measuring more than one autoantibody will increase the likelihood of a positive value, but it is also more costly.</p><p></p><p class="bulletIndent1">Insulin antibodies generally should not be measured for diagnostic purposes if the patient has received insulin therapy because some insulins can generate anti-insulin antibody formation. Nonetheless, this phenomenon is less common with human or analog insulins, which are the predominant insulins in clinical use.</p><p></p><p class="bulletIndent1">If two or more of the autoantibodies are present, the patient should be presumed to have type 1 diabetes and should be treated promptly with insulin replacement therapy, as these patients respond poorly to diet and oral hypoglycemic drug therapy. During early stages in the development of type 1 diabetes, intensive insulin therapy may prolong beta cell function [<a href="#rid23">23</a>], although this benefit was not found in some studies in children and adolescents [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1811.html" rel="external">"Type 1 diabetes mellitus: Prevention and disease-modifying therapy", section on 'Preserving insulin secretion in clinical disease'</a>.)</p><p></p><p class="bulletIndent1">The presence of antibodies to GAD, islet cell, insulin, the tyrosine phosphatases (IA-2 and IA-2 beta), and ZnT8 in patients with presumed type 2 diabetes can identify patients who may have latent autoimmune diabetes in adults [LADA]) and are more likely to require insulin [<a href="#rid4">4,9-11,26</a>]. (See <a class="local">'Latent autoimmune diabetes in adults (LADA)'</a> above.)</p><p></p><p class="bulletIndent1">Given the risk of DKA, insulin should also be started in any patient (regardless of whether they are thought to have type 1 or type 2 diabetes) who is catabolic (weight loss or dehydration in the setting of hyperglycemia), or who has evidence of increased ketogenesis (ketonuria or acidosis). Indications for insulin therapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Indications for insulin'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">GENETIC VARIANTS</span><span class="headingEndMark"> — </span>As the human genome is further explored, it is likely that multiple genetic variations at different loci will be found that confer varying degrees of predisposition to type 1 and type 2 diabetes. Polymorphisms of multiple genes are reported to influence the risk of type 1A diabetes, including genes in both the major histocompatibility complex (MHC) and elsewhere in the genome, but only human leukocyte antigen (HLA) alleles have a large effect, followed by insulin gene polymorphisms, and PTPN22. (See  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p>Numerous common polymorphisms weakly contribute to the risk for or protection from type 2 diabetes [<a href="#rid27">27</a>]. The genes encode proteins that affect several pathways leading to diabetes, including pancreatic development; insulin synthesis, processing, and secretion; amyloid deposition in beta cells; cellular insulin resistance; adipose tissue dysfunction; and impaired regulation of gluconeogenesis. Monogenic causes of type 2 diabetes represent only a small fraction of cases and commonly inherited polymorphisms individually contribute only small degrees of risk for, or protection from, diabetes. Most of the genetic risk for type 2 diabetes results from complex polygenic risk factors. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Monogenic diabetes (formerly called maturity onset diabetes of the young)</span><span class="headingEndMark"> — </span>Monogenic diabetes or maturity onset diabetes of the young (MODY) is a clinically heterogeneous disorder characterized by diabetes diagnosed at a young age (&lt;25 years) with autosomal dominant transmission and lack of autoantibodies [<a href="#rid28">28</a>]. MODY is the most common form of monogenic diabetes, accounting for 2 to 5 percent of diabetes [<a href="#rid29">29,30</a>]. The population prevalence of MODY in the United Kingdom is estimated to be 68 to 108 cases per million [<a href="#rid31">31</a>]. These patients are quite heterogeneous, and clinical characteristics may not be reliable in predicting the underlying pathogenesis [<a href="#rid32">32,33</a>]. Many patients are misclassified as having either type 1 or 2 diabetes.</p><p>Several different genetic abnormalities have been identified, each leading to a different type of disease. The original MODY nomenclature ("MODY1," "MODY2," "MODY3," etc) has been superseded by the term "monogenic diabetes" with the name of the gene associated with the trait. Well-understood, known monogenic gene variants and the associated syndromes are described below and in the table  (<a class="graphic graphic_table graphicRef83071" data-inline-graphics="83071" href="/z/d/graphic/83071.html" rel="external">table 3</a>). The genes involved control pancreatic beta cell development, function, and regulation, and the variants in these genes cause impaired glucose sensing and insulin secretion with minimal or no defect in insulin action [<a href="#rid34">34</a>]. Variants in hepatocyte nuclear factor-1-alpha (<em>HNF1A</em>) and the glucokinase (<em>GCK</em>) gene are most commonly identified, occurring in 52 to 65 and 15 to 32 percent of MODY cases, respectively [<a href="#rid33">33,35</a>]. Pathogenic variants in hepatocyte nuclear factor-4-alpha (<em>HNF4A</em>)<em> </em>account for approximately 10 percent of MODY cases. Some members of a family have the genetic defect but do not develop diabetes; the reason for this is unclear. Other patients may have the MODY phenotype but do not have a known pathogenic variant in any of the known MODY genes [<a href="#rid34">34</a>]. Finally, the increasing prevalence of obesity in the overall population can superimpose insulin resistance on MODY pathophysiology.</p><p class="headingAnchor" id="H10"><span class="h3">Hepatocyte nuclear factor-4-alpha</span><span class="headingEndMark"> — </span>Pathogenic variants in the <em>HNF4A</em> gene on chromosome 20 cause the condition formerly called MODY1 [<a href="#rid36">36</a>]. <em>HNF4A</em> is expressed both in the liver and in pancreatic beta cells. The precise mechanism by which a defect in <em>HNF4A</em> causes hyperglycemia is not clear, but it has been associated with reduced insulin secretory response to glucose, suggesting a primary genetic defect in insulin secretion [<a href="#rid37">37-39</a>]. The secretory defect is progressive, and patients typically present with hyperglycemia in adolescence or early childhood. Patients respond to sulfonylureas but may require insulin as the secretory defect progresses. These patients are at risk for the hyperglycemia-associated microvascular and macrovascular complications of diabetes.</p><p>Although <em>HNF4A</em> plays a central role in the hepatic synthesis of lipoprotein and coagulation proteins, these functions are largely maintained in <em>HNF4A</em> diabetes, suggesting that this disorder is primarily one of impaired pancreatic beta cell function [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Glucokinase</span><span class="headingEndMark"> — </span>More than 30 pathogenic variants in the <em>GCK</em> gene on chromosome 7 have been described and were formerly called MODY2 [<a href="#rid40">40</a>]. Defects in the expression of <em>GCK</em>, which phosphorylates glucose to glucose-6-phosphate and acts as a glucose sensor, result in a higher threshold for glucose-stimulated insulin secretion. On occasion, the expressed enzyme is functional but unstable, leading to an insulin secretory deficit [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/1785.html" rel="external">"Pancreatic beta cell function"</a>.)</p><p>The resulting hyperglycemia is often stable and mild (eg, fasting glucose 97 to 150 mg/dL [5.4 to 8.3 mmol/L] and glycated hemoglobin [A1C] 5.8 to 7.6 percent) [<a href="#rid42">42</a>], and is therefore not associated with the vascular complications common in other types of diabetes [<a href="#rid43">43</a>]. Patients with a pathogenic variant in the <em>GCK</em> gene can often be managed with diet alone.</p><p>In pregnant individuals with GCK-MODY, management depends on the fetal genotype. If the fetus inherits the maternal <em>GCK</em> variant (which will prevent fetal hyperinsulinemia and excessive growth despite maternal hyperglycemia), maternal hyperglycemia does not require treatment. However, if the fetus does not inherit the pathogenic variant, maternal insulin therapy is indicated to prevent excessive fetal growth. Fetal ultrasound with measurement of abdominal circumference has been used to predict fetal genotype but has limited diagnostic utility. In an international cohort of 38 pregnant women with GCK-MODY, fetal genetic testing using cell-free DNA in maternal blood had higher sensitivity (100 versus 53 percent) and specificity (96 versus 61 percent) than measurement of fetal abdominal circumference for prenatal diagnosis of GCK-MODY [<a href="#rid44">44</a>]. Thus, when available, noninvasive prenatal genotyping should be used to guide management of GCK-MODY during pregnancy.</p><p class="headingAnchor" id="H12"><span class="h3">Hepatocyte nuclear factor-1-alpha</span><span class="headingEndMark"> — </span>One of several pathogenic variants in the <em>HNF1A</em> gene on chromosome 12 was formerly called MODY3 [<a href="#rid45">45</a>]. This form of diabetes is more common among Europeans [<a href="#rid46">46,47</a>]. <em>HNF1A</em> is a weak transactivator of the insulin gene in beta cells. Variants of <em>HNF1A</em> can lead to abnormal insulin secretion; whether this or some other action is defective enough to cause diabetes mellitus is unclear [<a href="#rid47">47</a>]. Genetic variants also result in a low renal threshold for glucose. Thus, prior to onset of diabetes, mutation carriers have detectable glycosuria provoked by glucose loading [<a href="#rid48">48</a>]. Testing for glycosuria two hours after a glucose load could be used to screen children of variant carriers and guide the need for further evaluation.</p><p>Patients with <em>HNF1A</em> diabetes have a similar clinical phenotype as patients with <em>HNF4A</em> diabetes, perhaps since <em>HNF1A</em> is regulated positively by <em>HNF4A</em>. Patients exhibit increased insulin sensitivity and marked sensitivity to the hypoglycemic effects of sulfonylureas compared with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> and compared with patients with type 2 diabetes (3.9-fold greater reduction in fasting plasma glucose) [<a href="#rid49">49</a>]. Thus, patients with pathogenic variants in the <em>HNF1A</em> gene can be successfully treated with sulfonylurea monotherapy, and in one clinical study, approximately 70 percent of patients previously treated with insulin successfully switched to sulfonylureas once an <em>HNF1A</em> mutation was identified [<a href="#rid50">50</a>]. These patients are at risk for micro- and macrovascular complications of diabetes. In addition, patients with diabetes caused by a mutation in <em>HNF1A</em> appear to have an increased risk of cardiovascular mortality compared with unaffected family members [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Insulin promoter factor 1</span><span class="headingEndMark"> — </span>Pathogenic variants in the insulin promoter factor 1 (<em>IPF1</em>) gene can lead to what was called MODY4 by reduced binding of the protein to the insulin gene promoter [<a href="#rid52">52,53</a>] and perhaps by altering fibroblast growth factor signaling in beta cells [<a href="#rid54">54</a>]. Less severe variants in <em>IPF1</em> may predispose to late-onset type 2 diabetes [<a href="#rid53">53,55</a>]. In addition, carriers without diabetes have higher blood glucose concentrations and lower insulin-to-glucose ratios than family members without a pathogenic variant (and without diabetes) [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Hepatocyte nuclear factor-1-beta</span><span class="headingEndMark"> — </span>Pathogenic variants in the hepatocyte nuclear factor-1-beta (<em>HNF1B</em>) gene produce a syndrome formerly called MODY5 [<a href="#rid57">57-60</a>]. Affected patients can develop a variety of manifestations in addition to early-onset diabetes. These include pancreatic atrophy (on computed tomography [CT] scan), abnormal renal development (renal dysplasia that can be detected on ultrasonography in the fetus, single or multiple renal cysts, glomerulocystic disease, oligomeganephronia [a form of renal hypoplasia]), slowly progressive renal insufficiency, hypomagnesemia, elevated serum aminotransferases, and genital abnormalities (epididymal cysts, atresia of vas deferens, and bicornuate uterus) [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/6144.html" rel="external">"Kidney cystic diseases in children", section on 'Genetic disorders'</a> and  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia", section on 'Hepatocyte nuclear factor-1-beta gene mutations'</a> and  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia"</a> and  <a class="medical medical_review" href="/z/d/html/6083.html" rel="external">"Renal hypodysplasia", section on 'Genetic disorders'</a>.)</p><p>In addition, some patients have a phenotype consistent with autosomal dominant tubulointerstitial kidney disease. (See  <a class="medical medical_review" href="/z/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease", section on 'Other types of ADTKD'</a>.)</p><p>One of the functions of <em>HNF1B</em> is the regulation of tissue-specific gene expression. In the kidney, the proximal promoter of the <em>PKHD1</em> gene has a binding site for <em>HNF1B</em>. Pathogenic variants in <em>HNF1B</em> inhibit the expression of <em>PKHD1</em> and lead to cyst formation [<a href="#rid60">60</a>]. This is not surprising, since pathogenic variants in <em>PKHD1 </em>are responsible for the autosomal recessive form of polycystic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/6138.html" rel="external">"Autosomal recessive polycystic kidney disease in children", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Neurogenic differentiation factor 1</span><span class="headingEndMark"> — </span>Pathogenic variants in the gene for neurogenic differentiation factor 1 (also called <em>NEUROD1 </em>or <em>BETA2</em>) can lead to what was called MODY6 [<a href="#rid61">61,62</a>]. <em>NEUROD1</em> normally functions as a regulatory switch for endocrine pancreatic development.</p><p class="headingAnchor" id="H3753980"><span class="h3">Other genes</span><span class="headingEndMark"> — </span>Pathogenic variants in carboxyl ester lipase (<em>CEL</em>) (see <a class="local">'Genetically linked disorders of both exocrine and endocrine pancreatic lineages'</a> below); insulin (<em>INS</em>); ATP-binding cassette, subfamily C, member 8 (<em>ABCC8</em>); potassium channel, inwardly rectifying, subfamily J, member 11 (<em>KCNJ11</em>); and paternal uniparental isodisomy of chromosome 6q24 (UPD6) genes have been associated with the MODY phenotype [<a href="#rid34">34</a>]. Pathogenic variants in <em>INS</em>, <em>ABCC8</em>, and <em>KCNJ11</em> are more commonly associated with neonatal diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Neonatal diabetes mellitus'</a>.)</p><p>Monogenic diabetes diagnosed after infancy also has been attributed to pathogenic variants in tRNA methyltransferase 10A (<em>TRMT10A</em>), DNA heat shock protein family member C3 (<em>DNAJC3</em>), and deoxyuridine triphosphatase (<em>DUT</em>) [<a href="#rid63">63</a>]. These and other emerging and established monogenic diabetes genes are listed in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.diabetesgenes.org%2Ftests-for-diabetes-subtypes%2Ftargeted-next-generation-sequencing-analysis-of-45-monogenic-diabetes-genes%2F&amp;token=y%2BzIdlZV4o6ojU30ECXSsUHHvM4%2FShmUT3aRJBmrpSqXvsd%2BZ%2BS7j0ZzEKuAPUhw5jV8oLlY%2BlD2Mz3t5jRSLxJducCkuJUQdc3Z95QhzOAx81Q%2Bno6ryFyjcvw3r%2Bfo9mWfErMT3VZeFpICZEtf5Q%3D%3D&amp;TOPIC_ID=1793" target="_blank">University of Exeter panel of diabetes genes</a>.</p><p class="headingAnchor" id="H3754064"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>A suspected diagnosis of monogenic diabetes should be confirmed by diagnostic genetic testing. When available, comprehensive, panel-based, next-generation sequencing is preferred to single gene analysis, unless the clinical phenotype or family history strongly implicates a specific underlying genetic variant [<a href="#rid63">63</a>]. Laboratories in several countries offer clinical testing, primarily for variants in <em>HNF4A</em>, <em>HNF1A</em>, and <em>GCK</em>. A list of laboratories that provide genetic testing is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=1793" target="_blank">Genetic Testing Registry</a>. Only CLIA (Clinical Laboratory Improvement Amendments)-certified labs should be used. Genetic testing should only be performed after informed consent and genetic counseling. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Practical issues'</a>.)</p><p>It is important to distinguish monogenic diabetes from type 1 and type 2 diabetes because the optimal treatment and risk for diabetes complications varies with the underlying genetic defect  (<a class="graphic graphic_table graphicRef83072" href="/z/d/graphic/83072.html" rel="external">table 2</a>). As an example, patients with monogenic diabetes due to <em>HNF1A</em> or <em>HNF4A</em> variants are frequently misdiagnosed as having insulin-requiring type 1 diabetes because they present at an early age and in the absence of obesity. However, many of these patients can be successfully managed with sulfonylurea monotherapy. In addition, distinguishing monogenic diabetes from type 1 and type 2 diabetes allows earlier identification of at-risk family members.</p><p class="headingAnchor" id="H4885959"><span class="h3">Indications for genetic testing</span><span class="headingEndMark"> — </span>In all patients, it is important to obtain a detailed history of diabetes at diagnosis, including age, body mass index (BMI), and presenting symptoms [<a href="#rid64">64</a>]. It is also important to ascertain insulin dependency and the presence or absence of family history of diabetes. Genetic testing for monogenic diabetes should be performed when there is a high index of suspicion, as indicated by any of the following [<a href="#rid31">31,34,65,66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multigenerational family history of diabetes (eg, ≥3 generations or history in one parent and at least one other first-degree relative of that parent) with other clinical characteristics described above and in the table  (<a class="graphic graphic_table graphicRef83072" href="/z/d/graphic/83072.html" rel="external">table 2</a>) and negative autoantibodies to glutamic acid decarboxylase 65 (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transporter (ZnT8) [<a href="#rid63">63</a>]. In a patient with presumed type 1 diabetes, measurement of serum autoantibodies (islet cell antibodies [ICA], GAD65, insulin, tyrosine phosphatases IA-2 and IA-2 beta) should be performed prior to consideration of genetic testing for MODY. The presence of type 1 diabetes-associated islet autoantibodies makes monogenic diabetes unlikely [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high probability of monogenic diabetes (eg, &gt;25 percent in people not treated with insulin) using the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.diabetesgenes.org%2Fexeter-diabetes-app%2F&amp;token=o0NKMo%2FctGTsSXqQbfR9ZH0YtJY9WjsYxxmrqg5CToC%2F%2BlsW4xXGMyeqFiPxWs7JlBaQXxZ8i2iT1BTAQkCyYw%3D%3D&amp;TOPIC_ID=1793" target="_blank">MODY Clinical Risk Calculator</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In individuals with presumed type 1 diabetes, preserved fasting C-peptide (&gt;0.6 ng/mL [0.2 nmol/L] when glucose is &gt;72 mg/dL [4 mmol/L]) three to five years after initial presentation.</p><p></p><p>Differentiation between monogenic diabetes and other atypical forms of diabetes or type 2 diabetes may be difficult. For patients with presumed type 2 diabetes, the presence of a simple (non-multigenerational) family history does not discriminate between monogenic and type 2 diabetes. Further, pathogenic variants may arise de novo, so the absence of a family history of diabetes does not exclude the possibility of monogenic diabetes. Insulin resistance is not a common feature of monogenic diabetes. Thus, diabetes in the absence of obesity is suspicious for monogenic diabetes, particularly in adolescents with presumed type 2 diabetes. However, the absence of obesity or surrogate markers of insulin resistance is, in general, a poor discriminator between monogenic diabetes and type 2 diabetes in adults [<a href="#rid31">31,64</a>]. There are no biochemical tests that reliably differentiate between the two diseases.</p><p>For family members of pathogenic variant carriers, biochemical testing to confirm diabetes should be performed before genetic testing is considered [<a href="#rid65">65</a>]. If the biochemical tests are consistent with a diagnosis of diabetes, genetic testing can be performed to confirm the diagnosis of a monogenic diabetes subtype. (See  <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic criteria'</a>.)</p><p>Detailed current guidance on genetic testing and counseling for monogenic diabetes may be obtained at the National Society of Guidance Counselors practice resource [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Other beta cell gene defects</span><span class="headingEndMark"> — </span>Other rare genetic defects in beta cell function can cause diabetes. One type results from a dominantly inherited missense mutation in the sulfonylurea 1 receptor subunit (<em>SUR1</em>) that causes hyperinsulinemia in childhood, but beta cell dysfunction and diabetes in adulthood [<a href="#rid68">68,69</a>] (see  <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">"Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism"</a>). Other examples include point variants in mitochondrial DNA [<a href="#rid70">70</a>], genetic abnormalities that result in the inability to convert proinsulin to insulin [<a href="#rid71">71</a>], and production of mutant insulin molecules [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Genetic defects in insulin action</span><span class="headingEndMark"> — </span>Rare abnormalities in the insulin receptor (due to a genetic defect) or in the structure of insulin itself can cause impaired insulin signaling and diabetes. (See  <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">"Insulin resistance: Definition and clinical spectrum"</a>.)</p><p class="headingAnchor" id="H1167825525"><span class="h2">Genetic defects in mitochondrial DNA</span><span class="headingEndMark"> — </span>A pathogenic variant in position 3243 of mitochondrial DNA (m.3243 A&gt;G) causes a range of disease manifestations, including diabetes. Approximately 10 percent of patients with this variant have a syndrome termed MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes). The syndrome of maternally inherited diabetes and deafness (MIDD) is more common. MIDD has significant phenotypic variation depending on the degree of heteroplasmy (ie, the ratio of the variant mitochondrial DNA to wild-type mitochondrial DNA in the cells), but patients with clinically defined MIDD have both a defect in insulin secretion, which progresses to insulin dependence, and sensorineural hearing loss. The mean age of onset of diabetes and hearing loss is between 30 and 40 years [<a href="#rid73">73</a>]. Other manifestations include cardiac conduction defects, gestational diabetes, proteinuria, and neuropathy.</p><p>Although subjects may be treated with insulin secretagogues until insulin dependence develops, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is less effective and carries a higher risk of lactic acidosis in this population [<a href="#rid73">73,74</a>]. Supplementation with CoQ10 may be of some benefit. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Lactic acidosis'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Wolfram syndrome</span><span class="headingEndMark"> — </span>Another example of a rare genetic syndrome associated with diabetes is the Wolfram or DIDMOAD (arginine vasopressin deficiency [AVP-D; formerly diabetes insipidus], diabetes mellitus, optic atrophy, and deafness) syndrome [<a href="#rid75">75,76</a>]. This disorder is inherited as an autosomal recessive trait with incomplete penetrance. Two forms of Wolfram syndrome (WFS1 and WFS2) have been identified with different causative genes but overlapping phenotypes.</p><p>The first gene discovered to cause Wolfram syndrome, named <em>WFS1</em>, encodes an endoplasmic reticulum membrane-embedded protein called wolframin that is expressed in pancreatic beta cells and neurons [<a href="#rid77">77-79</a>]. The second, named <em>WFS2</em> (also called CDSGH iron sulfur domain 2, or <em>CISD2</em>), encodes a protein in the outer mitochondrial membrane [<a href="#rid80">80</a>]. The estimated prevalence of Wolfram syndrome is 1 in 770,000, and it is believed to occur in 1 of 150 patients with a phenotype of type 1 diabetes [<a href="#rid79">79</a>].</p><p>Affected patients usually develop insulin-requiring diabetes and optic atrophy in early childhood. WFS1 patients also develop AVP-D as teenagers or young adults [<a href="#rid81">81</a>], whereas WFS2 patients may not develop AVP-D and may present with bleeding due to platelet dysfunction. In WFS1, AVP-D is due to loss of vasopressin-secreting neurons in the supraoptic nucleus and impaired processing of vasopressin precursors [<a href="#rid82">82</a>] (see  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>). Anterior pituitary dysfunction has also been reported [<a href="#rid79">79</a>].</p><p>Other manifestations of Wolfram syndrome include progressive sensorineural deafness, hydronephrosis in WFS1 (due in part to the high urine flow in AVP-D), and neurologic dysfunction [<a href="#rid83">83</a>]. Why severe insulin-requiring diabetes develops is not known; immunologic factors do not appear to be important [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H3094885579"><span class="h2">Fulminant diabetes</span><span class="headingEndMark"> — </span>This distinctive form of diabetes, termed a "subtype" of type 1 diabetes, was originally described in Japan and has been reported predominantly in a series of case reports in adults of Far Eastern descent [<a href="#rid84">84</a>]. It is characterized by presentation in diabetic ketoacidosis (DKA) of persons with no prior history of diabetes, who remain completely insulin-dependent following this abrupt onset. Acute beta cell destruction is the cause, presumably due to either a hitherto uncharacterized viral infection or a novel form of islet autoimmunity against a background of genetic susceptibility. The Japan Diabetes Society has proposed the following diagnostic criteria [<a href="#rid85">85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Occurrence of diabetic ketosis or DKA within approximately seven days after onset of hyperglycemic symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma glucose &gt;288 mg/dL and A1C &lt;8.5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasting serum C‐peptide &lt;0.3 ng/mL (or &lt;0.5 ng/mL after glucagon stimulation)</p><p></p><p>Intensive insulin therapy is required lifelong following recovery from DKA.</p><p>Other emerging forms of diabetes with acute, severe presentation include checkpoint inhibitor-associated diabetes and SARS-CoV-2 (COVID-19) associated diabetes. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Drug-induced hyperglycemia'</a> and  <a class="medical medical_review" href="/z/d/html/128127.html" rel="external">"COVID-19: Issues related to diabetes mellitus in adults", section on 'Clinical presentations'</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">DISEASES OF THE EXOCRINE PANCREAS</span><span class="headingEndMark"> — </span>Any disease that damages the pancreas, or surgical removal of pancreatic tissue (eg, for treatment of congenital hyperinsulinism or for pancreatic cancer), can result in diabetes. There is wide variability in the frequency with which this occurs, primarily determined by the degree of pancreatic insufficiency [<a href="#rid86">86</a>]. In general, in the absence of other risk factors for diabetes, removal of as much as one-half to three-quarters of the pancreas may not result in clinical diabetes if the remaining pancreas functions normally. Among patients with pancreatic exocrine disease, diabetes is more likely to occur in those with a family history of type 1 or type 2 diabetes. This observation suggests a role for an underlying decrease in pancreatic reserve or in insulin responsiveness that makes overt diabetes more likely in patients with pancreatic insufficiency. (See  <a class="medical medical_review" href="/z/d/html/5648.html" rel="external">"Overview of the complications of chronic pancreatitis", section on 'Pancreatic diabetes'</a> and  <a class="medical medical_review" href="/z/d/html/91408.html" rel="external">"Surgical resection of lesions of the head of the pancreas", section on 'New-onset diabetes'</a>.)</p><p>Diabetes that occurs in patients with pancreatic disease is usually insulin requiring. However, it is different from type 1 diabetes in that the glucagon-producing alpha cells are also affected. As a result, risk of insulin-induced hypoglycemia is higher.</p><p class="headingAnchor" id="H21"><span class="h2">Cystic fibrosis</span><span class="headingEndMark"> — </span>The mechanisms of cystic fibrosis-related diabetes are unique and share features with both type 1 and type 2 diabetes, with both decreased insulin production and insulin resistance [<a href="#rid87">87,88</a>]. Patients with no pancreatic exocrine deficiency have normal insulin secretion and responsiveness. In comparison, patients with exocrine deficiency have decreased insulin secretion, but often glucose tolerance remains normal despite increased hepatic glucose production [<a href="#rid89">89</a>] because increased energy expenditure (glucose utilization) occurs concomitantly. Patients with exocrine deficiency and either impaired glucose tolerance or overt diabetes have reductions in both peripheral glucose utilization and hepatic insulin sensitivity. (See  <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Cystic fibrosis-related diabetes mellitus'</a> and  <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease", section on 'Cystic fibrosis-related diabetes'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Hereditary hemochromatosis</span><span class="headingEndMark"> — </span>Diabetes is common in patients with hereditary hemochromatosis, being present at diagnosis in up to 50 percent of symptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Chronic pancreatitis</span><span class="headingEndMark"> — </span>Glucose intolerance occurs with some frequency in chronic pancreatitis, but overt diabetes mellitus usually occurs late in the course of disease. (See  <a class="medical medical_review" href="/z/d/html/5649.html" rel="external">"Chronic pancreatitis: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5896.html" rel="external">"Clinical manifestations and diagnosis of chronic and acute recurrent pancreatitis in children"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Fibrocalculous pancreatic diabetes</span><span class="headingEndMark"> — </span>Fibrocalculous pancreatic diabetes is a unique form of diabetes secondary to tropical pancreatitis that is endemic in certain parts of the world (eg, southern India). In a prospective evaluation of 370 patients, all of the macro- and microvascular complications typically associated with diabetes were found. Pancreatic cancer and complications of chronic pancreatitis also contribute to the mortality associated with this disease [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/5646.html" rel="external">"Etiology and pathogenesis of chronic pancreatitis in adults"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Genetically linked disorders of both exocrine and endocrine pancreatic lineages</span><span class="headingEndMark"> — </span>Both exocrine and endocrine pancreatic cells originate from the same endodermal pool. A genetic factor common to both endocrine and exocrine pancreatic development may account for some cases of pancreatic exocrine dysfunction with diabetes. Norwegian kindreds with an autosomal dominant inheritance pattern for diabetes and exocrine pancreatic dysfunction have been identified with a single-base deletion in the carboxyl ester lipase (<em>CEL</em>) gene [<a href="#rid91">91</a>]. The mechanism by which carboxyl ester lipase deficiency in pancreatic acinar cells is linked to beta cell failure is not known [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H26"><span class="h1">ENDOCRINOPATHIES</span><span class="headingEndMark"> — </span>Several hormones, such as epinephrine, glucagon, cortisol, and growth hormone, antagonize the action of insulin. Release of these hormones constitutes the protective counterregulatory response to hypoglycemia. On the other hand, primary oversecretion of these hormones can result in impaired fasting glucose or overt diabetes. (See  <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p>Endocrine abnormalities that can lead to abnormalities in glucose regulation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome, due to pituitary or adrenal disease or to exogenous glucocorticoid administration. (See  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acromegaly. (See  <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catecholamine excess in pheochromocytoma. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucagon-secreting tumors (glucagonomas), associated with an unusual constellation of other clinical features, including skin rash, weight loss, anemia, and thromboembolic problems. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Somatostatin-secreting tumors (somatostatinomas), typically associated with the triad of diabetes mellitus, cholelithiasis, and diarrhea with steatorrhea. (See  <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism, which can interfere with glucose metabolism, although overt diabetes is unusual. (See  <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">DRUG-INDUCED DIABETES</span><span class="headingEndMark"> — </span>A large number of drugs can impair glucose tolerance; they act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin. This topic is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Drug-induced hyperglycemia'</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">VIRAL INFECTIONS</span><span class="headingEndMark"> — </span>Certain viruses (eg, Coxsackie, mumps, SARS-CoV-2) can cause diabetes, either through direct beta cell destruction or, hypothetically, by inducing autoimmune damage (see  <a class="medical medical_review" href="/z/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>). Chronic hepatitis C virus infection has been associated with an increased incidence of diabetes, but it is uncertain if there is a cause-and-effect relationship. (See  <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection", section on 'Diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H3342720079"><span class="h2">COVID-19 associated diabetes</span><span class="headingEndMark"> — </span>SARS-CoV-2 (COVID-19) appears to precipitate severe manifestations of diabetes in patients with or without a prior history of diabetes, including diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and severe insulin resistance. This topic is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128127.html" rel="external">"COVID-19: Issues related to diabetes mellitus in adults", section on 'Clinical presentations'</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">GESTATIONAL DIABETES MELLITUS</span><span class="headingEndMark"> — </span>Gestational diabetes occurs when a woman's insulin secretory capacity is not sufficient to overcome both the insulin resistance created by the anti-insulin hormones secreted by the placenta during pregnancy (eg, estrogen, prolactin, human placental lactogen, cortisol, and progesterone) and the increased fuel consumption necessary to provide for the growing mother and fetus. It is estimated to occur in approximately 2.1 percent of pregnant women in the United States, usually developing in the second or third trimester. (See  <a class="medical medical_review" href="/z/d/html/6797.html" rel="external">"Gestational diabetes mellitus: Screening, diagnosis, and prevention"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">UNCOMMON IMMUNE-MEDIATED DIABETES</span><span class="headingEndMark"> — </span>Several uncommon forms of immune-mediated diabetes have been identified.</p><p class="headingAnchor" id="H31"><span class="h2">Stiff-person syndrome</span><span class="headingEndMark"> — </span>The stiff-person syndrome (formerly called stiff-man syndrome) is an autoimmune disorder of the central nervous system, which is characterized by progressive muscle stiffness, rigidity, and spasm involving the axial muscles, with severe impairment of ambulation. Patients usually have high titers of anti-glutamic acid decarboxylase (GAD) antibodies, and diabetes occurs in approximately one-third of cases. (See  <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">"Stiff-person syndrome"</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Anti-insulin receptor antibodies</span><span class="headingEndMark"> — </span>Anti-insulin receptor antibodies can bind to insulin receptors and either act as an agonist, leading to hypoglycemia, or block the binding of insulin and cause diabetes [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2676293001"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15401.html" rel="external">"Patient education: Type 1 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15402.html" rel="external">"Patient education: Type 2 diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1736.html" rel="external">"Patient education: Type 1 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 diabetes</strong> – Type 1 diabetes is characterized by destruction of the pancreatic beta cells, leading to absolute insulin deficiency. This is usually due to autoimmune destruction of the pancreatic beta cells. (See <a class="local">'Type 1 diabetes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 diabetes</strong> – Type 2 diabetes is by far the most common type of diabetes and is characterized by variable degrees of insulin resistance and deficiency. (See <a class="local">'Type 2 diabetes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Difficulty distinguishing between type 1 diabetes and atypical presentation of type 2 diabetes</strong> – When the diagnosis of type 1 or type 2 diabetes is uncertain by clinical presentation (eg, patient with poor response to initial therapy with sulfonylureas or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, personal or family history of autoimmune disease), we measure at least two autoantibodies (glutamic acid decarboxylase 65 [GAD65], insulin, tyrosine phosphatases [insulinoma-associated protein 2 (IA-2) and IA-2 beta], islet cell, or zinc transporter 8 [ZnT8]). If two or more of the autoantibodies are present, the patient should be presumed to have type 1 diabetes and should be treated with insulin replacement therapy, as these patients respond poorly to diet and oral hypoglycemic drug therapy. (See <a class="local">'Distinguishing type 1 from type 2 diabetes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic variants</strong> – As the human genome is further explored, multiple genetic variants at different loci likely will be found that confer varying degrees of predisposition to type 1 and type 2 diabetes. Monogenic causes of type 2 diabetes represent a fraction of cases, and commonly inherited polymorphisms individually contribute only small degrees of risk for, or protection from, diabetes. Most of the genetic risk for type 2 diabetes results from complex polygenic risk factors. (See <a class="local">'Genetic variants'</a> above and  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Genetic susceptibility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monogenic diabetes</strong> – Monogenic diabetes, formerly referred to as maturity onset diabetes of the young (MODY), is a clinically heterogeneous disorder characterized by onset of diabetes at a young age (&lt;25 years) with autosomal dominant transmission and absence of diabetes-related autoantibodies. It is classified by the underlying genetic defect  (<a class="graphic graphic_table graphicRef83071" href="/z/d/graphic/83071.html" rel="external">table 3</a>). Many patients with monogenic diabetes are misclassified as having either type 1 or 2 diabetes  (<a class="graphic graphic_table graphicRef83072" href="/z/d/graphic/83072.html" rel="external">table 2</a>). (See <a class="local">'Monogenic diabetes (formerly called maturity onset diabetes of the young)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – The diagnosis of monogenic diabetes (MODY) is made by performing diagnostic genetic testing by either next-generation, gene panel-based sequencing or sequencing of a specific gene when strongly implicated by clinical phenotype. Laboratories in several countries offer clinical testing, including panels for the most common genetic variants: hepatocyte nuclear factor-4-alpha (<em>HNF4A</em>), hepatocyte nuclear factor-1-alpha (<em>HNF1A</em>), and glucokinase (<em>GCK)</em>. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2">We typically perform genetic testing for monogenic diabetes (MODY) when there is a high index of suspicion (familial diabetes with autosomal dominant pattern of inheritance [≥3 generations or an affected parent who has at least one other first-degree relative with diabetes], onset &lt;25 years, negative islet autoantibodies)  (<a class="graphic graphic_table graphicRef83072" href="/z/d/graphic/83072.html" rel="external">table 2</a>). For family members of mutation carriers, biochemical testing to confirm diabetes should be performed before genetic testing is considered. If the biochemical tests are consistent with a diagnosis of diabetes, genetic testing can be performed to confirm the diagnosis of a monogenic diabetes subtype. (See <a class="local">'Indications for genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diseases of the exocrine pancreas</strong> – Diseases that damage the pancreas, or surgical removal of pancreatic tissue, can result in diabetes. There is wide variability in the frequency with which this occurs, primarily determined by the degree of pancreatic insufficiency. (See <a class="local">'Diseases of the exocrine pancreas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrinopathies</strong> – Several endocrinopathies, including Cushing syndrome, acromegaly, and pheochromocytoma, can lead to abnormalities in glucose regulation. (See <a class="local">'Endocrinopathies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced diabetes</strong> – A large number of drugs can impair glucose tolerance; they act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin. (See  <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">"Pathogenesis of type 2 diabetes mellitus", section on 'Drug-induced hyperglycemia'</a>.)</p><p></p><p class="headingAnchor" id="H1012494068"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges David McCulloch, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S20.</a></li><li><a class="nounderline abstract_t">Chiang JL, Kirkman MS, Laffel LM, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.</a></li><li><a class="nounderline abstract_t">Maruyama T, Nakagawa T, Kasuga A, Murata M. Heterogeneity among patients with latent autoimmune diabetes in adults. Diabetes Metab Res Rev 2011; 27:971.</a></li><li><a class="nounderline abstract_t">Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42:359.</a></li><li><a class="nounderline abstract_t">Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91:1654.</a></li><li><a class="nounderline abstract_t">Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94:4635.</a></li><li><a class="nounderline abstract_t">Wei Y, Herzog K, Ahlqvist E, et al. All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults. Diabetes Care 2023; 46:1857.</a></li><li><a class="nounderline abstract_t">Fourlanos S, Perry C, Stein MS, et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29:970.</a></li><li><a class="nounderline abstract_t">Niskanen LK, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18:1557.</a></li><li><a class="nounderline abstract_t">Falorni A, Gambelunghe G, Forini F, et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 2000; 85:309.</a></li><li><a class="nounderline abstract_t">Borg H, Gottsäter A, Landin-Olsson M, et al. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86:3032.</a></li><li><a class="nounderline abstract_t">Zhu Y, Qian L, Liu Q, et al. Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function. Diabetes Metab J 2020; 44:260.</a></li><li><a class="nounderline abstract_t">Harris MI, Robbins DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994; 17:1337.</a></li><li><a class="nounderline abstract_t">Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990; 33:561.</a></li><li><a class="nounderline abstract_t">Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008; 57:1433.</a></li><li><a class="nounderline abstract_t">Lukacs K, Hosszufalusi N, Dinya E, et al. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia 2012; 55:689.</a></li><li><a class="nounderline abstract_t">Pettersen E, Skorpen F, Kvaløy K, et al. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health Study. Diabetes 2010; 59:302.</a></li><li><a class="nounderline abstract_t">Chang DC, Piaggi P, Hanson RL, et al. Use of a High-Density Protein Microarray to Identify Autoantibodies in Subjects with Type 2 Diabetes Mellitus and an HLA Background Associated with Reduced Insulin Secretion. PLoS One 2015; 10:e0143551.</a></li><li><a class="nounderline abstract_t">Brooks-Worrell B, Hampe CS, Hattery EG, et al. Islet Autoimmunity is Highly Prevalent and Associated With Diminished β-Cell Function in Patients With Type 2 Diabetes in the Grade Study. Diabetes 2022; 71:1261.</a></li><li><a class="nounderline abstract_t">Ahlqvist E, Prasad RB, Groop L. Subtypes of Type 2 Diabetes Determined From Clinical Parameters. Diabetes 2020; 69:2086.</a></li><li><a class="nounderline abstract_t">Udler MS, Kim J, von Grotthuss M, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med 2018; 15:e1002654.</a></li><li><a class="nounderline abstract_t">Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52:2623.</a></li><li><a class="nounderline abstract_t">Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128:517.</a></li><li><a class="nounderline abstract_t">Boughton CK, Allen JM, Ware J, et al. Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes. N Engl J Med 2022; 387:882.</a></li><li><a class="nounderline abstract_t">McVean J, Forlenza GP, Beck RW, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329:980.</a></li><li><a class="nounderline abstract_t">Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104:17040.</a></li><li><a class="nounderline abstract_t">Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018; 50:1505.</a></li><li><a class="nounderline abstract_t">Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975; 24:44.</a></li><li><a class="nounderline abstract_t">Gat-Yablonski G, Shalitin S, Phillip M. Maturity onset diabetes of the young--review. Pediatr Endocrinol Rev 2006; 3 Suppl 3:514.</a></li><li><a class="nounderline abstract_t">McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 2011; 28:1028.</a></li><li><a class="nounderline abstract_t">Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343:d6044.</a></li><li><a class="nounderline abstract_t">Dussoix P, Vaxillaire M, Iynedjian PB, et al. Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes 1997; 46:622.</a></li><li><a class="nounderline abstract_t">Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971.</a></li><li><a class="nounderline abstract_t">Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75:422.</a></li><li><a class="nounderline abstract_t">Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53:2504.</a></li><li><a class="nounderline abstract_t">Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384:458.</a></li><li><a class="nounderline abstract_t">Herman WH, Fajans SS, Ortiz FJ, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994; 43:40.</a></li><li><a class="nounderline abstract_t">Lindner T, Gragnoli C, Furuta H, et al. Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4alpha/MODY1 gene. J Clin Invest 1997; 100:1400.</a></li><li><a class="nounderline abstract_t">Gupta RK, Vatamaniuk MZ, Lee CS, et al. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 2005; 115:1006.</a></li><li><a class="nounderline abstract_t">Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697.</a></li><li><a class="nounderline abstract_t">Kesavan P, Wang L, Davis E, et al. Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2). Biochem J 1997; 322 ( Pt 1):57.</a></li><li><a class="nounderline abstract_t">Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care 2015; 38:1383.</a></li><li><a class="nounderline abstract_t">Velho G, Blanché H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997; 40:217.</a></li><li><a class="nounderline abstract_t">Hughes AE, Houghton JAL, Bunce B, et al. Bringing precision medicine to the management of pregnancy in women with glucokinase-MODY: a study of diagnostic accuracy and feasibility of non-invasive prenatal testing. Diabetologia 2023; 66:1997.</a></li><li><a class="nounderline abstract_t">Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384:455.</a></li><li><a class="nounderline abstract_t">Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996; 276:1246.</a></li><li><a class="nounderline abstract_t">Hansen T, Eiberg H, Rouard M, et al. Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes 1997; 46:726.</a></li><li><a class="nounderline abstract_t">Stride A, Ellard S, Clark P, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care 2005; 28:1751.</a></li><li><a class="nounderline abstract_t">Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362:1275.</a></li><li><a class="nounderline abstract_t">Shepherd M, Shields B, Ellard S, et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26:437.</a></li><li><a class="nounderline abstract_t">Steele AM, Shields BM, Shepherd M, et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27:157.</a></li><li><a class="nounderline abstract_t">Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17:138.</a></li><li><a class="nounderline abstract_t">Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 1999; 104:R33.</a></li><li><a class="nounderline abstract_t">Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000; 408:864.</a></li><li><a class="nounderline abstract_t">Hani EH, Stoffers DA, Chèvre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104:R41.</a></li><li><a class="nounderline abstract_t">Weng J, Macfarlane WM, Lehto M, et al. Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. Diabetologia 2001; 44:249.</a></li><li><a class="nounderline abstract_t">Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997; 17:384.</a></li><li><a class="nounderline abstract_t">Bellanné-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004; 140:510.</a></li><li><a class="nounderline abstract_t">Woolf AS, Feather SA, Bingham C. Recent insights into kidney diseases associated with glomerular cysts. Pediatr Nephrol 2002; 17:229.</a></li><li><a class="nounderline abstract_t">Hiesberger T, Bai Y, Shao X, et al. Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice. J Clin Invest 2004; 113:814.</a></li><li><a class="nounderline abstract_t">Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 1999; 23:323.</a></li><li><a class="nounderline abstract_t">Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1. Diabetologia 2001; 44:2098.</a></li><li><a class="nounderline abstract_t">Greeley SAW, Polak M, Njølstad PR, et al. ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2022; 23:1188.</a></li><li><a class="nounderline abstract_t">Bellanné-Chantelot C, Lévy DJ, Carette C, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab 2011; 96:E1346.</a></li><li><a class="nounderline abstract_t">Ellard S, Bellanné-Chantelot C, Hattersley AT, European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51:546.</a></li><li><a class="nounderline abstract_t">Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab 2021; 106:237.</a></li><li><a class="nounderline abstract_t">Maloney KA, Mizerik E, King RH, et al. Genetic counseling in diabetes mellitus: A practice resource of the National Society of Genetic Counselors. J Genet Couns 2023.</a></li><li><a class="nounderline abstract_t">Huopio H, Reimann F, Ashfield R, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 2000; 106:897.</a></li><li><a class="nounderline abstract_t">Huopio H, Otonkoski T, Vauhkonen I, et al. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003; 361:301.</a></li><li><a class="nounderline abstract_t">Johns DR. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med 1995; 333:638.</a></li><li><a class="nounderline abstract_t">Robbins DC, Shoelson SE, Rubenstein AH, Tager HS. Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion. J Clin Invest 1984; 73:714.</a></li><li><a class="nounderline abstract_t">Tager H, Given B, Baldwin D, et al. A structurally abnormal insulin causing human diabetes. Nature 1979; 281:122.</a></li><li><a class="nounderline abstract_t">Donovan LE, Severin NE. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol Metab 2006; 91:4737.</a></li><li><a class="nounderline abstract_t">Kim NH, Siddiqui M, Vogel J. MELAS Syndrome and MIDD Unmasked by Metformin Use: A Case Report. Ann Intern Med 2021; 174:124.</a></li><li><a class="nounderline abstract_t">Cremers CW, Wijdeveld PG, Pinckers AJ. Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (Wolfram syndrome). A review of 88 cases from the literature with personal observations on 3 new patients. Acta Paediatr Scand Suppl 1977; :1.</a></li><li><a class="nounderline abstract_t">Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995; 346:1458.</a></li><li><a class="nounderline abstract_t">Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20:143.</a></li><li><a class="nounderline abstract_t">Strom TM, Hörtnagel K, Hofmann S, et al. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 1998; 7:2021.</a></li><li><a class="nounderline abstract_t">Boutzios G, Livadas S, Marinakis E, et al. Endocrine and metabolic aspects of the Wolfram syndrome. Endocrine 2011; 40:10.</a></li><li><a class="nounderline abstract_t">Pallotta MT, Tascini G, Crispoldi R, et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med 2019; 17:238.</a></li><li><a class="nounderline abstract_t">Ray MK, Chen L, White NH, et al. Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience. Pediatr Diabetes 2022; 23:212.</a></li><li><a class="nounderline abstract_t">Gabreëls BA, Swaab DF, de Kleijn DP, et al. The vasopressin precursor is not processed in the hypothalamus of Wolfram syndrome patients with diabetes insipidus: evidence for the involvement of PC2 and 7B2. J Clin Endocrinol Metab 1998; 83:4026.</a></li><li><a class="nounderline abstract_t">Chaussenot A, Bannwarth S, Rouzier C, et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol 2011; 69:501.</a></li><li><a class="nounderline abstract_t">Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342:301.</a></li><li><a class="nounderline abstract_t">Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 2012; 3:536.</a></li><li><a class="nounderline abstract_t">Del Prato S, Tiengo A. Pancreatic diabetes. Diabetes Reviews 1993; 1:260.</a></li><li><a class="nounderline abstract_t">Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994; 43:1020.</a></li><li><a class="nounderline abstract_t">O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009; 10 Suppl 12:43.</a></li><li><a class="nounderline abstract_t">Kien CL, Horswill CA, Zipf WB, et al. Elevated hepatic glucose production in children with cystic fibrosis. Pediatr Res 1995; 37:600.</a></li><li><a class="nounderline abstract_t">Mohan V, Premalatha G, Padma A, et al. Fibrocalculous pancreatic diabetes. Long-term survival analysis. Diabetes Care 1996; 19:1274.</a></li><li><a class="nounderline abstract_t">Raeder H, Johansson S, Holm PI, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet 2006; 38:54.</a></li><li><a class="nounderline abstract_t">Hattersley AT. Beyond the beta cell in diabetes. Nat Genet 2006; 38:12.</a></li><li><a class="nounderline abstract_t">Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41:1473.</a></li></ol></div><div id="topicVersionRevision">Topic 1793 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078589" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935775" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Type 1 diabetes through the life span: a position statement of the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22069295" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Heterogeneity among patients with latent autoimmune diabetes in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425674" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16478821" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837918" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Latent autoimmune diabetes in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644622" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A clinical screening tool identifies autoimmune diabetes in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722051" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634404" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443164" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769235" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821176" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of adult-onset IDDM in the U.S. population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2253834" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310307" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109281" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606528" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of a High-Density Protein Microarray to Identify Autoantibodies in Subjects with Type 2 Diabetes Mellitus and an HLA Background Associated with Reduced Insulin Secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35061024" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Islet Autoimmunity is Highly Prevalent and Associated With Diminishedβ-Cell Function in Patients With Type 2 Diabetes in the Grade Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32843567" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subtypes of Type 2 Diabetes Determined From Clinical Parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30240442" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514648" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518395" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069870" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36826834" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942684" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297969" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1122063" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551475" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Maturity onset diabetes of the young--review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21395678" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22012810" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and management of maturity onset diabetes of the young (MODY).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075802" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575290" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521318" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Who should have genetic testing for maturity-onset diabetes of the young?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20499044" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Maturity-onset diabetes of the young (MODY): how many cases are we missing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8945471" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262315" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294105" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4alpha/MODY1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761495" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433729" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078243" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26106223" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049484" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37653058" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bringing precision medicine to the management of pregnancy in women with glucokinase-MODY: a study of diagnostic accuracy and feasibility of non-invasive prenatal testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8945470" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849753" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075819" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983330" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14575972" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Genetic cause of hyperglycaemia and response to treatment in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19388975" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546258" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326926" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early-onset type-II diabetes mellitus (MODY4) linked to IPF1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545530" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130726" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Attenuation of FGF signalling in mouse beta-cells leads to diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545531" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11270685" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398836" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068978" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956871" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recent insights into kidney diseases associated with glomerular cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15067314" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545951" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719843" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537518" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : ISPAD Clinical Practice Consensus Guidelines 2022: The diagnosis and management of monogenic diabetes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21677039" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18297260" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33034350" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Approach to the Patient with MODY-Monogenic Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37537905" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Genetic counseling in diabetes mellitus: A practice resource of the National Society of Genetic Counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11018078" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559865" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637726" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368587" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/381941" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A structurally abnormal insulin causing human diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018649" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32833489" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : MELAS Syndrome and MIDD Unmasked by Metformin Use: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/270276" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (Wolfram syndrome). A review of 88 cases from the literature with personal observations on 3 new patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7490992" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771706" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817917" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21725703" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Endocrine and metabolic aspects of the Wolfram syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337416" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34792267" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814487" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The vasopressin precursor is not processed in the hypothalamus of Wolfram syndrome patients with diabetes insipidus: evidence for the involvement of PC2 and 7B2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21446023" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neurologic features and genotype-phenotype correlation in Wolfram syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655528" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24843620" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pancreatic diabetes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039595" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Insulin sensitivity in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19754617" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Management of cystic fibrosis-related diabetes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603777" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Elevated hepatic glucose production in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8908394" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fibrocalculous pancreatic diabetes. Long-term survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369531" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380722" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Beyond the beta cell in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327927" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
